46 related articles for article (PubMed ID: 22780935)
1. Neoadjuvant Chemotherapy in Patients with HER2-Negative Breast Cancer: A Report from Clinical Breast Cancer Registry of Iran.
Roudini K; Mirzania M; Yavari T; Seyyedsalehi MS; Nahvijou A; Zebardast J; Saadat M; Khajeh-Mehrizi A
Arch Iran Med; 2024 Apr; 27(4):206-215. PubMed ID: 38685847
[TBL] [Abstract][Full Text] [Related]
2. Both carboplatin and bevacizumab improve pathological complete remission rate in neoadjuvant treatment of triple negative breast cancer: a meta-analysis.
Chen XS; Yuan Y; Garfield DH; Wu JY; Huang O; Shen KW
PLoS One; 2014; 9(9):e108405. PubMed ID: 25247558
[TBL] [Abstract][Full Text] [Related]
3. Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B.
DiGiovanna MP; Stern DF; Edgerton S; Broadwater G; Dressler LG; Budman DR; Henderson IC; Norton L; Liu ET; Muss HB; Berry DA; Hayes DF; Thor AD
J Clin Oncol; 2008 May; 26(14):2364-72. PubMed ID: 18390970
[TBL] [Abstract][Full Text] [Related]
4. Basal-like breast carcinomas: clinical outcome and response to chemotherapy.
Banerjee S; Reis-Filho JS; Ashley S; Steele D; Ashworth A; Lakhani SR; Smith IE
J Clin Pathol; 2006 Jul; 59(7):729-35. PubMed ID: 16556664
[TBL] [Abstract][Full Text] [Related]
5. Higher efficacy and reduced adverse reactions in neoadjuvant chemotherapy for breast cancer by using pegylated liposomal doxorubicin compared with pirarubicin.
Liu W; Chen W; Zhang X; Zhao P; Fan Z; Bi L; Wu D; Li S; Yang M; Fu T; Song D; Han B; Zhao G; Du Y; Shi A
Sci Rep; 2021 Jan; 11(1):199. PubMed ID: 33420241
[TBL] [Abstract][Full Text] [Related]
6. Extending Adjuvant Endocrine Therapy in Breast Cancer: Who, What, Why?
Vinayak S; Davidson NE
Oncology (Williston Park); 2019 Jun; 33(6):243-6. PubMed ID: 31219612
[TBL] [Abstract][Full Text] [Related]
7. Relationship between quantitative GRB7 RNA expression and recurrence after adjuvant anthracycline chemotherapy in triple-negative breast cancer.
Sparano JA; Goldstein LJ; Childs BH; Shak S; Brassard D; Badve S; Baehner FL; Bugarini R; Rowley S; Perez EA; Shulman LN; Martino S; Davidson NE; Kenny PA; Sledge GW; Gray R
Clin Cancer Res; 2011 Nov; 17(22):7194-203. PubMed ID: 21933890
[TBL] [Abstract][Full Text] [Related]
8. Radiation-induced angiosarcoma of the breast: individual participant meta-analysis of Japanese population.
Takehara Y; Matsuda N; Kobayashi D; Yoshida A; Takei J; Kanomata N; Tsunoda H; Yamauchi H; Hayashi N
Breast Cancer; 2023 Sep; 30(5):739-747. PubMed ID: 37261705
[TBL] [Abstract][Full Text] [Related]
9. Designing adjuvant treatment based on biological measurements in the neoadjuvant setting.
Smith IE; Kotsori A
Breast Cancer Res; 2010 Dec; 12 Suppl 4(Suppl 4):S16. PubMed ID: 21172078
[No Abstract] [Full Text] [Related]
10. Combination chemotherapy with pirarubicin (THP), cyclophosphamide, vincristine, and prednisolone (VEP-THP therapy) in the treatment of non-Hodgkin's lymphoma.
Takagi T; Sakai C; Oguro M
Oncology; 1990; 47(1):25-8. PubMed ID: 2300381
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant chemotherapy of breast cancer with pirarubicin versus epirubicin in combination with cyclophosphamide and docetaxel.
Gu X; Jia S; Wei W; Zhang WH
Tumour Biol; 2015 Jul; 36(7):5529-35. PubMed ID: 25682286
[TBL] [Abstract][Full Text] [Related]
12. [Phase II clinical trial of neoadjuvant therapy with carboplatin plus paclitaxel for locally advanced triple-negative breast cancer].
Ma WY; Zhang P; Zhang BL; Wang X; Xu XZ; Zheng S; Wang JY; Cai RG; Yuan P; Ma F; Fan Y; Xu BH
Zhonghua Zhong Liu Za Zhi; 2012 Oct; 34(10):770-4. PubMed ID: 23291072
[TBL] [Abstract][Full Text] [Related]
13. Pathologic response to short intensified taxane-free neoadjuvant chemotherapy in patients with highly proliferative operable breast cancer.
Le Tourneau C; Dettwiler S; Beuzeboc P; Alran S; Laurence V; Pierga JY; Fréneaux P; Sigal-Zafrani B; Diéras V; Vincent-Salomon A
Am J Clin Oncol; 2012 Jun; 35(3):242-6. PubMed ID: 21358298
[TBL] [Abstract][Full Text] [Related]
14. Current strategy for triple-negative breast cancer: appropriate combination of surgery, radiation, and chemotherapy.
Yagata H; Kajiura Y; Yamauchi H
Breast Cancer; 2011 Jul; 18(3):165-73. PubMed ID: 21290263
[TBL] [Abstract][Full Text] [Related]
15. Variability in hormone and growth factor receptor expression in primary versus recurrent, metastatic, and post-neoadjuvant breast carcinoma.
Jabbour MN; Massad CY; Boulos FI
Breast Cancer Res Treat; 2012 Aug; 135(1):29-37. PubMed ID: 22484731
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy analysis of THP-containing regimens as neoadjuvant and adjuvant chemotherapy for primary breast cancer].
Wang LZ; Ouyang T; Wang TF; Xie YT; Fan ZQ; Fan T; Lin BY; Li JF
Zhonghua Zhong Liu Za Zhi; 2012 Feb; 34(2):143-6. PubMed ID: 22780935
[TBL] [Abstract][Full Text] [Related]
17. [Neoadjuvant chemotherapy for primary breast cancer].
Li JF; Ouyang T; Wang TF; Lin BY
Zhonghua Zhong Liu Za Zhi; 2004 Aug; 26(8):493-5. PubMed ID: 15555342
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
